Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers. (8th October 2022)

• Record Type: Journal Article
• Authors: Lin, Chunxiu; Liu, Peng; Shi, Chaowen; Qiu, Lipeng; Shang, Dongsheng; Lu, Ziwen; Tu, Zhigang; Liu, Hanqing
• Is Part Of: Fundamental & clinical pharmacology. Volume 37:Number 2(2023)
• Page Start: 194
• Page End: 214
• Publication Date: 2022-10-08
• Subjects: small molecular drugs -- ovarian cancer -- DNA repair -- PAPR inhibitors -- epigenetic modifications; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/fcp.12834
• Languages: English
• ISSNs: 0767-3981

Abstract

Abstract: The susceptibility of cells to DNA damage and their DNA repair ability are crucial for cancer therapy. Homologous recombination is one of the major repairing mechanisms for DNA double‐strand breaks. Approximately half of ovarian cancer (OvCa) cells harbor homologous recombination deficiency (HRD). Considering that HRD is a major hallmark of OvCas, scholars proposed HRD scoring to evaluate the HRD degree and guide the choice of therapeutic strategies for OvCas. In the last decade, synthetic lethal strategy by targeting poly (ADP‐ribose) polymerase (PARP) in HR‐deficient OvCas has attracted considerable attention in view of its favorable clinical effort. We therefore suggested that the uses of other DNA damage/repair‐targeted drugs in HR‐deficient OvCas might also offer better clinical outcome. Here, we reviewed the current small molecule compounds that targeted DNA damage/repair pathways and discussed the HRD scoring system to guide their clinical uses.